KRAS and invasive carcinoma: So, in all precursor lesions and invasive carcinomas, activating KRAS mutations led to a significant Abi1 overexpression against the background of the already existing upregulation in consequence of adenomatous change, perhaps related to enhanced PI3K/Akt signalling in these lesions [33].